CY1112218T1 - Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν - Google Patents

Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν

Info

Publication number
CY1112218T1
CY1112218T1 CY20111101051T CY111101051T CY1112218T1 CY 1112218 T1 CY1112218 T1 CY 1112218T1 CY 20111101051 T CY20111101051 T CY 20111101051T CY 111101051 T CY111101051 T CY 111101051T CY 1112218 T1 CY1112218 T1 CY 1112218T1
Authority
CY
Cyprus
Prior art keywords
preparation
vitronectine
competitive
receptors
medicinal
Prior art date
Application number
CY20111101051T
Other languages
English (en)
Inventor
Jean-Marie Ruxer
Jean-Michel Lefrancois
Bertrand Heckmann
Original Assignee
Galapagos Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Sas filed Critical Galapagos Sas
Publication of CY1112218T1 publication Critical patent/CY1112218T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η ευρεσιτεχνία έχει ως αντικείμενο ενώσεις του τύπου (Ι) στον οποίο τα R1, R2, R3, R4 και G είναι όπως ορίζεται στην περιγραφή, τη μέθοδο παρασκευής τους, τη χρήση τους ως φάρμακα που έχουν δράση ανταγωνιστή υποδοχέα βιτρονεκτίνης και φαρμακευτικές συνθέσεις που τις περιέχουν.
CY20111101051T 2002-11-19 2011-11-02 Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν CY1112218T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
EP09003174A EP2070914B1 (fr) 2002-11-19 2003-11-12 Nouveaux dérivés antagonistes du récepteur de la vitronectine, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
CY1112218T1 true CY1112218T1 (el) 2015-12-09

Family

ID=32187700

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101051T CY1112218T1 (el) 2002-11-19 2011-11-02 Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν

Country Status (28)

Country Link
US (2) US7582640B2 (el)
EP (2) EP2070914B1 (el)
JP (1) JP4567459B2 (el)
KR (1) KR101140752B1 (el)
CN (2) CN101928287A (el)
AR (2) AR042068A1 (el)
AT (2) ATE518842T1 (el)
AU (2) AU2003299330B2 (el)
BR (1) BR0316307A (el)
CA (1) CA2506310C (el)
CO (1) CO5700761A2 (el)
CY (1) CY1112218T1 (el)
DE (1) DE60327712D1 (el)
DK (2) DK1565467T3 (el)
ES (2) ES2325616T3 (el)
FR (1) FR2847254B1 (el)
HK (2) HK1076277A1 (el)
IL (2) IL168136A (el)
MA (1) MA27492A1 (el)
MX (1) MXPA05005340A (el)
NO (1) NO20052491D0 (el)
PL (1) PL376866A1 (el)
PT (2) PT1565467E (el)
RU (1) RU2412185C2 (el)
SI (2) SI1565467T1 (el)
TW (1) TW200412969A (el)
WO (1) WO2004048375A1 (el)
ZA (1) ZA200502850B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
SI3613739T1 (sl) 2018-08-17 2021-02-26 Oxurion NV Integrinski antagonisti
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
EP4171212A1 (en) 2020-06-29 2023-05-03 Ickovic & Bliss, Inc. Systems, methods, and program products for digital pet identification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
WO1994008577A1 (en) 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
AU675689B2 (en) 1992-12-01 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
ES2186720T3 (es) 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
AU702661B2 (en) 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
JP2000516575A (ja) 1996-06-28 2000-12-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング インテグリンインヒビターとしてのフェニルアラニン誘導体
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
IL137423A0 (en) 1998-01-23 2001-07-24 Aventis Pharma Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CA2333927A1 (en) * 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
CZ2001447A3 (cs) * 1998-08-07 2001-08-15 Smithkline Beecham Corporation Antagonista receptoru vitronektinu
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
CN1197645C (zh) * 1999-10-05 2005-04-20 德比尔斯工业钻石股份有限公司 金刚石晶簇的生长
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
NO20052491L (no) 2005-05-23
AR077476A2 (es) 2011-08-31
CN1738817B (zh) 2011-12-21
DK1565467T3 (da) 2009-09-14
AU2003299330A1 (en) 2004-06-18
EP1565467A1 (fr) 2005-08-24
US7582640B2 (en) 2009-09-01
MXPA05005340A (es) 2005-11-17
IL168136A (en) 2012-06-28
CO5700761A2 (es) 2006-11-30
AU2003299330B2 (en) 2009-09-17
IL205693A (en) 2011-06-30
HK1129372A1 (en) 2009-11-27
TW200412969A (en) 2004-08-01
CA2506310C (fr) 2014-04-08
US20090149476A1 (en) 2009-06-11
AU2009212779A1 (en) 2009-09-17
RU2412185C2 (ru) 2011-02-20
DK2070914T3 (da) 2011-11-21
NO20052491D0 (no) 2005-05-23
ZA200502850B (en) 2005-10-25
DE60327712D1 (de) 2009-07-02
ES2369561T3 (es) 2011-12-01
PT1565467E (pt) 2009-07-15
HK1076277A1 (en) 2006-01-13
RU2005119163A (ru) 2006-02-27
FR2847254A1 (fr) 2004-05-21
ATE518842T1 (de) 2011-08-15
AR042068A1 (es) 2005-06-08
SI2070914T1 (sl) 2012-02-29
JP4567459B2 (ja) 2010-10-20
EP2070914A1 (fr) 2009-06-17
AU2009212779B2 (en) 2011-09-01
CN1738817A (zh) 2006-02-22
CA2506310A1 (fr) 2004-06-10
EP2070914B1 (fr) 2011-08-03
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
BR0316307A (pt) 2005-09-27
CN101928287A (zh) 2010-12-29
WO2004048375A1 (fr) 2004-06-10
PT2070914E (pt) 2011-10-12
KR20050083926A (ko) 2005-08-26
ATE431825T1 (de) 2009-06-15
SI1565467T1 (sl) 2009-10-31
FR2847254B1 (fr) 2005-01-28
ES2325616T3 (es) 2009-09-10
PL376866A1 (pl) 2006-01-09
JP2006508999A (ja) 2006-03-16
US20060052398A1 (en) 2006-03-09
KR101140752B1 (ko) 2012-05-03
EP1565467B1 (fr) 2009-05-20

Similar Documents

Publication Publication Date Title
CY1112218T1 (el) Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
CY1111705T1 (el) Παραγωγα 2-αζα-δικυκλο[3.1.0]εξανιου ως ανταγωνιστες του υποδοχεα ορεξινης
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
HRP20050933A2 (en) Organic compounds
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
CY1113639T1 (el) Παραγωγα βενζαμιδιου και ετεροαρενιου
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
CY1108378T1 (el) 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
CY1109787T1 (el) Ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
ECSP045367A (es) "derivados de bencimidazol utiles como antagonistas de histamina h3"
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) Therapeutic compounds
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE60322680D1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CY1109371T1 (el) Παραγωγα σουλφαμικου βενζοθειοφαινιου ως αναστολεις σουλφατασης στεροειδους
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung